REVIVA PHARMACEUTICALS HOLDINGS, INC. 8-K

What Happened

• Reviva Pharmaceuticals Holdings, Inc. announced and filed an 8-K on March 30, 2026 (Item 2.02) disclosing financial information and operating metrics for the fiscal year ended December 31, 2025. The company also discussed its business outlook in a press release dated March 30, 2026, which is furnished as Exhibit 99.1 to the filing.

Key Details

• Filing date: March 30, 2026 (Current Report on Form 8-K, Item 2.02).
• Reporting period: Fiscal year ended December 31, 2025.
• Disclosure format: Company issued a press release with results, operating metrics, and outlook (attached as Exhibit 99.1).
• The filing incorporates the press release by reference and includes the Interactive XBRL cover page.

Why It Matters

• This 8-K signals that Reviva has updated its investors with year‑end financial results and operating metrics and has provided a business outlook—information investors use to assess performance and outlook heading into the new fiscal year.
• The 8-K itself points you to the press release (Exhibit 99.1) for the specific numbers and commentary; investors should review that release and any subsequent filings (e.g., Form 10-K) for detailed revenue, earnings, cash position, and operational metrics before making decisions.